Nextpharma
Nextpharma, a leading contract development and manufacturing organisation (CDMO), is headquartered in Germany and operates extensively across Europe and North America. Founded in 2004, the company has established itself as a key player in the pharmaceutical industry, specialising in the development and production of complex drug formulations, including sterile and non-sterile products. Nextpharma's core services encompass a wide range of capabilities, from formulation development to commercial manufacturing, with a strong emphasis on quality and regulatory compliance. The company is recognised for its innovative approach and commitment to meeting the unique needs of its clients, which has solidified its market position. With a focus on delivering tailored solutions, Nextpharma continues to achieve significant milestones, enhancing its reputation as a trusted partner in the pharmaceutical landscape.
DitchCarbon Score
How does Nextpharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nextpharma's score of 13 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Nextpharma's reported carbon emissions
In 2023, Nextpharma reported total greenhouse gas emissions of approximately 6,131,000 kg CO2e for Scope 1 and about 6,951,000 kg CO2e for Scope 2, resulting in a combined total of around 13,082,000 kg CO2e for these scopes. Additionally, Scope 3 emissions were recorded at approximately 3,885,000 kg CO2e. Comparatively, in 2022, the company emitted about 6,461,000 kg CO2e for Scope 1 and around 5,947,000 kg CO2e for Scope 2, leading to a total of approximately 12,408,000 kg CO2e. This indicates a reduction in emissions from 2022 to 2023, particularly in Scope 1 and Scope 2 emissions. Nextpharma has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as the baseline year. Furthermore, the company is committed to a 25% reduction in absolute Scope 3 emissions within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to limiting global warming to 1.5°C. Overall, Nextpharma's ongoing efforts reflect a strong commitment to sustainability and climate action within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 7,519,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 7,740,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nextpharma is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
